Allianz Asset Management Gmb H Halozyme Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

$69.7 Billion
Q3 2024

A detailed history of Allianz Asset Management Gmb H transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 14,059 shares of HALO stock, worth $683,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,059

Previous 6,559 114.35%

Holding current value

$683,267

Previous $343,000 134.4%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$51.3 - $64.42 $384,750 - $483,150	7,500 Added 114.35%	14,059 $804,000
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $151,240 - $209,600	-4,000 Reduced 37.88%	6,559 $343,000
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $355,627 - $442,950	10,559 New	10,559 $429,000
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $18.5 Million - $23.7 Million	-610,778 Reduced 96.37%	23,037 $830,000
Q1 2023 May 11, 2023	BUY	$32.86 - $55.7 $480,971 - $815,280	14,637 Added 2.36%	633,815 $24.2 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $3.49 Million - $5.18 Million	-87,100 Reduced 12.33%	619,178 $35.2 Million
Q3 2022 Nov 08, 2022	SELL	$38.53 - $51.78 $1.56 Million - $2.09 Million	-40,411 Reduced 5.41%	706,278 $27.9 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $5.03 Million - $6.51 Million	134,729 Added 22.02%	746,689 $32.9 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $821,181 - $1.05 Million	25,686 Added 4.38%	611,960 $24.4 Million
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $800,623 - $1.03 Million	25,161 Added 4.48%	586,274 $23.6 Million
Q3 2021 Nov 10, 2021	BUY	$38.47 - $46.42 $11.9 Million - $14.4 Million	309,327 Added 122.85%	561,113 $22.8 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $8.46 Million - $11.2 Million	217,880 Added 642.6%	251,786 $11.4 Million
Q1 2021 May 13, 2021	SELL	$39.51 - $51.45 $2.27 Million - $2.96 Million	-57,522 Reduced 62.92%	33,906 $1.41 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $369,779 - $624,943	14,327 Added 18.58%	91,428 $3.91 Million
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $1.25 Million - $1.44 Million	-48,684 Reduced 38.7%	77,101 $2.03 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $1.71 Million - $2.82 Million	105,043 Added 506.43%	125,785 $3.37 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $2.21 Million - $3.46 Million	-158,710 Reduced 88.44%	20,742 $373,000
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $2.68 Million - $3.5 Million	179,452 New	179,452 $3.18 Million
Q3 2019 Nov 13, 2019	SELL	$15.2 - $17.69 $1.69 Million - $1.96 Million	-110,968 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$14.75 - $17.26 $8,230 - $9,631	558 Added 0.51%	110,968 $1.91 Million
Q1 2019 May 13, 2019	BUY	$13.94 - $17.58 $1.54 Million - $1.94 Million	110,410 New	110,410 $1.78 Million
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $268,706 - $376,148	-20,158 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$16.68 - $18.41 $636,125 - $702,102	-38,137 Reduced 65.42%	20,158 $366,000
Q1 2018 May 14, 2018	SELL	$17.06 - $21.2 $97,173 - $120,755	-5,696 Reduced 8.9%	58,295 $1.14 Million
Q4 2017 Feb 13, 2018	SELL	$16.75 - $20.8 $206,326 - $256,214	-12,318 Reduced 16.14%	63,991 $1.3 Million
Q3 2017 Nov 13, 2017	BUY	$11.76 - $17.4 $81,002 - $119,851	6,888 Added 9.92%	76,309 $1.33 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-74,100 Reduced 51.63%	69,421 $896,000
Q1 2017 Apr 17, 2019	BUY	N/A	8,539 Added 6.33%	143,521 $1.86 Million
Q4 2016 Apr 17, 2019	SELL	N/A	-92,938 Reduced 40.78%	134,982 $1.33 Million
Q3 2016 Apr 17, 2019	BUY	N/A	227,920	227,920 $2.74 Million

Others Institutions Holding HALO

# of Institutions

544

Shares Held

126M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.77B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.

Account

Allianz Asset Management Gmb H Halozyme Therapeutics, Inc. Transaction History